{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:38:51Z","timestamp":1780324731406,"version":"3.54.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1143,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s13311-020-00848-z","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T14:03:50Z","timestamp":1584021830000},"page":"955-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration"],"prefix":"10.1016","volume":"17","author":[{"given":"S. Richard","family":"Dunham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00848-z_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/514032","article-title":"Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy","volume":"176","author":"Weber","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1007\/s13311-020-00848-z_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J Med Virol"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol"},{"issue":"17","key":"10.1007\/s13311-020-00848-z_bib5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1007\/s13311-020-00848-z_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"NEJM"},{"issue":"17","key":"10.1007\/s13311-020-00848-z_bib7","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMc1816198","article-title":"Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab","volume":"380","author":"Walter","year":"2019","journal-title":"NEJM"},{"key":"10.1007\/s13311-020-00848-z_bib8","doi-asserted-by":"crossref","unstructured":"Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB. Progressive multifocal leukoencephalopathy treated with nivolumab. J Neurovirol 2019.","DOI":"10.1007\/s13365-019-00738-x"},{"key":"10.1007\/s13311-020-00848-z_bib9","doi-asserted-by":"crossref","unstructured":"Darvin P, Toor SM, Sasidharan NV, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50(165).","DOI":"10.1038\/s12276-018-0191-1"},{"issue":"15","key":"10.1007\/s13311-020-00848-z_bib10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1007\/s13311-020-00848-z_bib11","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/jac\/dkq359","article-title":"A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia","volume":"65","author":"Patel","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib12","doi-asserted-by":"crossref","first-page":"ofu074","DOI":"10.1093\/ofid\/ofu074","article-title":"Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy","volume":"1","author":"Gasnault","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1007\/s13311-020-00848-z_bib13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaneurol.2014.825","article-title":"Treatment of progressive multifocal leukoencephalopathy with interleukin 7","volume":"71","author":"Alstadhaug","year":"2014","journal-title":"JAMA Neurol"},{"issue":"15","key":"10.1007\/s13311-020-00848-z_bib14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks","year":"1984","journal-title":"Neurol Clin"},{"issue":"6","key":"10.1007\/s13311-020-00848-z_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s13365-014-0289-8","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"21","author":"Clifford","year":"2015","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-020-00848-z_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","article-title":"Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection","volume":"338","author":"Hall","year":"1998","journal-title":"NEnglJMed"},{"key":"10.1007\/s13311-020-00848-z_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200209060-00012","article-title":"A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS","volume":"16","author":"Marra","year":"2002","journal-title":"AIDS"},{"issue":"4","key":"10.1007\/s13311-020-00848-z_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/13550280152537274","article-title":"Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring","volume":"7","author":"Gasnault","year":"2001","journal-title":"J Neurovirol"},{"issue":"4","key":"10.1007\/s13311-020-00848-z_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J Neurovirol"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib21","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","article-title":"Identification and characterization of mefloquine efficacy against JC virus in vitro","volume":"53","author":"Brickelmaier","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1007\/s13311-020-00848-z_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","article-title":"Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine","volume":"36","author":"Jamilloux","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1007\/s13311-020-00848-z_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J Neurovirol"},{"issue":"1","key":"10.1007\/s13311-020-00848-z_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1007\/s13311-020-00848-z_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","article-title":"Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study","volume":"49","author":"Falco","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1007\/s13311-020-00848-z_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1086\/314937","article-title":"Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era","volume":"180","author":"Dworkin","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1007\/s13311-020-00848-z_bib27","first-page":"346","article-title":"Natural history of progressive multifocal leukoencephalopathy (PML) in AIDS modified by antiretroviral therapy","volume":"4","author":"Clifford","year":"1998","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-020-00848-z_bib28","doi-asserted-by":"crossref","unstructured":"Anand P, Hotan G, Vogel A, Venna N, Mateen FJ. Progressive multifocal leukoencephalopathy A 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 2019;6(6).","DOI":"10.1212\/NXI.0000000000000618"},{"issue":"7","key":"10.1007\/s13311-020-00848-z_bib29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1212\/WNL.0b013e31820c3089","article-title":"Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score","volume":"76","author":"Lanoy","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hiv.12008","article-title":"Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?","volume":"14","author":"Fanjul","year":"2013","journal-title":"HIV Med"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/427698","article-title":"Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy","volume":"40","author":"Bossolasco","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s13311-020-00848-z_bib32","unstructured":"Gheuens S, Bord E, Kesari S, Simpson D, Gandhi R, Clifford D, et al. Combined role of CD4+ and CD8+ T cell responses against JCV in the clinical outcome of patients with PML and PML-IRIS. 18th Conference on Retroviruses and Opportunistic Infections. 2011;416."},{"key":"10.1007\/s13311-020-00848-z_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib34","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-020-00848-z_bib35","doi-asserted-by":"crossref","unstructured":"Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017.","DOI":"10.1016\/S1474-4422(17)30282-X"},{"issue":"6","key":"10.1007\/s13311-020-00848-z_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive Multifocal Leukeoncephalopathy C. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-020-00848-z_bib37","doi-asserted-by":"crossref","unstructured":"Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015.","DOI":"10.1007\/s13365-015-0316-4"},{"key":"10.1007\/s13311-020-00848-z_bib38","doi-asserted-by":"crossref","unstructured":"Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep. 2013;13(408).","DOI":"10.1007\/s11910-013-0408-6"},{"issue":"4","key":"10.1007\/s13311-020-00848-z_bib39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00848-z_bib40","doi-asserted-by":"crossref","unstructured":"Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, et al. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. PLoS ONE. 2016;11(12).","DOI":"10.1371\/journal.pone.0168376"},{"key":"10.1007\/s13311-020-00848-z_bib41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00848-z_bib42","doi-asserted-by":"crossref","unstructured":"Scarpazza C, Prosperini L, De Rossi N, Moiola L, Sormani MP, Gerevini S, et al. To do or not to do? Plasma exchange and timing of steroid administration in PML. Ann Neurol. 2017.","DOI":"10.1002\/ana.25070"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/acn3.776","article-title":"Treatment of natalizumab-associated PML with filgrastim","volume":"6","author":"Stefoski","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1007\/s13311-020-00848-z_bib44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","article-title":"No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML","volume":"88","author":"Landi","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1304828","article-title":"Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome","volume":"370","author":"Giacomini","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1007\/s13311-020-00848-z_bib46","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/rheumatology\/kem299","article-title":"Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab","volume":"47","author":"Harris","year":"2008","journal-title":"Rheumatology"},{"issue":"6","key":"10.1007\/s13311-020-00848-z_bib48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-018-3552-x","article-title":"Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia","volume":"98","author":"Pejsa","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib49","first-page":"323","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neuro-Oncol"},{"issue":"17","key":"10.1007\/s13311-020-00848-z_bib50","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","article-title":"PML in a patient treated with fumaric acid","volume":"368","author":"Ermis","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1007\/s13311-020-00848-z_bib51","first-page":"1081","article-title":"Case reports of PML in patients treated for psoriasis","volume":"369","author":"Ermis","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1007\/s13311-020-00848-z_bib52","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1007\/s13311-020-00848-z_bib53","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMc1413724","article-title":"PML in a patient without severe lymphocytopenia receiving dimethyl fumarate","volume":"372","author":"Nieuwkamp","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1007\/s13311-020-00848-z_bib54","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/1352458519832259","article-title":"Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy","volume":"25","author":"Gerevini","year":"2019","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-020-00848-z_bib55","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","article-title":"Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation","volume":"86","author":"Neff","year":"2008","journal-title":"Transplantation"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-020-00848-z_bib57","doi-asserted-by":"crossref","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. [Review] [77 refs]. Lancet Oncol 2009;10(8):816\u201324.","DOI":"10.1016\/S1470-2045(09)70161-5"},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib58","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1007\/s13311-020-00848-z_bib59","unstructured":"Clifford D, Gass A, Richert N, Tornatore C, Vermersch P, Hughs R, et al. Cases reported as progressive multifocal leukoencephalopathy in Ocrelizumab-treated patients with multiple sclerosis. ECTRIMS abstract. 2019."},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib60","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.22408","article-title":"Progressive multifocal leukoencephalopathy in transplant recipients","volume":"70","author":"Mateen","year":"2011","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious disease","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","article-title":"Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy","volume":"60","author":"Tan","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib64","first-page":"284","article-title":"Progressive multifocal leukoencephalopathy treated with nivolumab","volume":"25","author":"Hoang","year":"2019","journal-title":"J Neuro-Oncol"},{"issue":"19","key":"10.1007\/s13311-020-00848-z_bib65","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","article-title":"Determinants of survival in progressive multifocal leukoencephalopathy","volume":"73","author":"Marzocchetti","year":"2009","journal-title":"Neurology"},{"issue":"23","key":"10.1007\/s13311-020-00848-z_bib66","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/bloodadvances.2017008201","article-title":"Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review","volume":"1","author":"Neil","year":"2017","journal-title":"Blood Adv"},{"issue":"20","key":"10.1007\/s13311-020-00848-z_bib67","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: A report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1007\/s13311-020-00848-z_bib68","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1212\/NXI.0000000000000628","article-title":"Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency","volume":"6","author":"Kupper","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1007\/s13311-020-00848-z_bib69","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1212\/NXI.0000000000000627","article-title":"Ineffective treatment of PML with pembrolizumab","volume":"6","author":"Pawlitzki","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1007\/s13311-020-00848-z_bib70","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3201\/eid2511.190705","article-title":"Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy","volume":"25","author":"Medrano","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1007\/s13311-020-00848-z_bib71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2011.01.011","article-title":"IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology","volume":"144","author":"Pellegrini","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1007\/s13311-020-00848-z_bib72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2011.01.038","article-title":"IL-7 Knocks the Socs Off Chronic Viral Infection","volume":"144","author":"Parish","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1007\/s13311-020-00848-z_bib73","first-page":"141","article-title":"JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7","volume":"23","author":"Soleimani-Meigooni","year":"2017","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"10.1007\/s13311-020-00848-z_bib74","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1212\/NXI.0000000000000213","article-title":"Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia","volume":"3","author":"Miskin","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1007\/s13311-020-00848-z_bib75","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.bmt.1701010","article-title":"Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2","volume":"20","author":"Przepiorka","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1007\/s13311-020-00848-z_bib76","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1701568","article-title":"Case report: Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy","volume":"23","author":"Re","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1007\/s13311-020-00848-z_bib77","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1212\/01.wnl.0000183064.10227.b5","article-title":"Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2","volume":"65","author":"Kunschner","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-020-00848-z_bib78","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciu682","article-title":"Treating Progressive Multifocal Leukoencephalopathy With Interleukin 7 and Vaccination With JC Virus Capsid Protein VP1","volume":"59","author":"Sospedra","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib79","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.celrep.2017.10.027","article-title":"Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses","volume":"21","author":"Geoghegan","year":"2017","journal-title":"Cell Rep"},{"key":"10.1007\/s13311-020-00848-z_bib80","doi-asserted-by":"crossref","unstructured":"Wollebo HS, Bellizzi A, Kaminski R, Hu W, White MK, Khalili K. CRISPR\/Cas9 System as an Agent fro Eliminating Polyomavirus JC Infection. PLoS ONE. 2015;10(9).","DOI":"10.1371\/journal.pone.0136046"},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib81","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000200","article-title":"Neurological immune reconstitution inflammatory response: riding the tide of immune recovery","volume":"28","author":"Clifford","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1007\/s13311-020-00848-z_bib82","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp-2013-304986","article-title":"Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?","volume":"84","author":"Wattjes","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1007\/s13311-020-00848-z_bib83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1148\/radiology.187.1.8451420","article-title":"Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation","volume":"187","author":"Whiteman","year":"1993","journal-title":"Radiology"},{"issue":"10","key":"10.1007\/s13311-020-00848-z_bib84","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2016-313772","article-title":"MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance","volume":"87","author":"Wijburg","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1007\/s13311-020-00848-z_bib85","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3174\/ajnr.A4436","article-title":"Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy","volume":"36","author":"Hodel","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1007\/s13311-020-00848-z_bib86","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-020-00848-z_bib87","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-020-00848-z_bib88","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/jnnp-2015-311411","article-title":"MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS","volume":"87","author":"Wattjes","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-020-00848-z_bib89","doi-asserted-by":"crossref","unstructured":"Sanchez P, Meca-Lallana V, J. Vivancos. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. Mult Scler Relat Disord. 2018;25:95\u20138.","DOI":"10.1016\/j.msard.2018.07.001"},{"issue":"1","key":"10.1007\/s13311-020-00848-z_bib90","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","volume":"75","author":"Fine","year":"2014","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1007\/s13311-020-00848-z_bib91","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1097\/QAD.0b013e32833365f4","article-title":"Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?","volume":"23","author":"Martin-Blondel","year":"2009","journal-title":"AIDS"},{"key":"10.1007\/s13311-020-00848-z_bib92","doi-asserted-by":"crossref","unstructured":"Sierra-Madero JG, Ellenberg SS, Rassool MS, Tierney A, Belaunzaran-Zamudio PF, Lopez-Martinez A, et al. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. Lancet HIV 2014;1(2).","DOI":"10.1016\/S2352-3018(14)70027-X"},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib93","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00401-015-1383-6","article-title":"Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome","volume":"129","author":"Martin-Blondel","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1007\/s13311-020-00848-z_bib94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00401-015-1391-6","article-title":"High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc","volume":"129","author":"Stork","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-020-00848-z_bib95","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jns.2017.05.018","article-title":"Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?","volume":"378","author":"Scarpazza","year":"2017","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1007\/s13311-020-00848-z_bib96","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1086\/315817","article-title":"The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy","volume":"182","author":"De Luca","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1007\/s13311-020-00848-z_bib97","first-page":"816","article-title":"Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy","volume":"45","author":"Yiannoutsos","year":"1999","journal-title":"AnnNeurol"},{"key":"10.1007\/s13311-020-00848-z_bib98","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids","volume":"72","author":"Tan","year":"2009","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00848-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-020-00848-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00848-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:42Z","timestamp":1761807462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923013132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1878747923013132"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00848-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00848-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}